var title_f11_22_11616="Arthritis in morphea";
var content_f11_22_11616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arthritis in morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A swollen right knee with effusion (lowest arrow) is present in this patient with morphea (upper arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11616=[""].join("\n");
var outline_f11_22_11616=null;
var title_f11_22_11617="Prifinium: International drug information";
var content_f11_22_11617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prifinium: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Padrin (JP);",
"     </li>",
"     <li>",
"      Prifinial (AT, CH, FR);",
"     </li>",
"     <li>",
"      Riabal (FR, IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1980103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Prifinium Bromide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1980105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Gastrointestinal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1980108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of gastrointestinal spasms",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1980104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: 30-60 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M., I.V., SubQ: 15 mg 2-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1980107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Injection, solution: 7.5 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Syrup: 7.5 mg/5 mL (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 15 mg, 30 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10431 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11617=[""].join("\n");
var outline_f11_22_11617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303429\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980103\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980105\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980108\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980104\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821194\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980107\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10431\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10431|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_22_11618="Idiopathic guttate hypomelanosis - thigh";
var content_f11_22_11618=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Idiopathic guttate hypomelanosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small, hypopigmented macules are present on the thigh.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11618=[""].join("\n");
var outline_f11_22_11618=null;
var title_f11_22_11619="Patient information: Preparing for hemodialysis (The Basics)";
var content_f11_22_11619=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16270\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/5/93\">",
"         Hemodialysis",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/38/6753\">",
"          Diagram showing AV fistula for hemodialysis",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/45/24273\">",
"           Diagram showing AV graft for hemodialysis",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/5/37969\">",
"            Diagram showing central venous catheter for hemodialysis",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/42/19107\">",
"         Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/35/28212\">",
"         Patient information: Chronic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/2/18467\">",
"         Patient information: Dialysis and diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/1/25619\">",
"         Patient information: Hemodialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/46/25315\">",
"         Patient information: Kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/33/8722\">",
"         Patient information: Low-potassium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/19/41266\">",
"         Patient information: Low-sodium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/43/16051\">",
"         Patient information: Peritoneal dialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/15/12531\">",
"         Patient information: Planning for a kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/26/9635\">",
"         Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/57/40852\">",
"         Patient information: Hemodialysis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/41/42640\">",
"         Patient information: Low potassium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/61/39890\">",
"         Patient information: Low sodium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Preparing for hemodialysis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/preparing-for-hemodialysis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H24824174\">",
"      <span class=\"h1\">",
"       What is hemodialysis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hemodialysis is a treatment for kidney failure. Normally, the kidneys work to filter the blood and remove waste and excess salt and water. Kidney failure, also called &ldquo;end-stage renal disease,&rdquo; is when the kidneys stop working completely.",
"     </p>",
"     <p>",
"      With hemodialysis, a machine takes over the job of the kidneys. The machine pumps blood out of the body, filters it, and returns it to the body (",
"      <a class=\"graphic graphic_figure graphicRef56992 \" href=\"UTD.htm?0/5/93\">",
"       figure 1",
"      </a>",
"      ). People have hemodialysis at least 3 times a week.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24824181\">",
"      <span class=\"h1\">",
"       When do I prepare for hemodialysis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will need to start preparing a few months before you begin hemodialysis treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24824188\">",
"      <span class=\"h1\">",
"       How do I prepare for hemodialysis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You prepare for hemodialysis by talking with your doctor, making certain choices, and having surgery.",
"     </p>",
"     <p>",
"      Before you start hemodialysis, you will need to choose where you have it. Most people can choose between having hemodialysis at a dialysis center (in a hospital or clinic) or at home. If you plan to have hemodialysis at home, you will need to get your home ready. You will need a dialysis machine and supplies. You might need to make changes to your home&rsquo;s plumbing or electricity.",
"     </p>",
"     <p>",
"      You also need to prepare your body for hemodialysis by having surgery ahead of time. Your doctor will create an &ldquo;access,&rdquo; which is a way for the blood to leave and return to your body during hemodialysis. An access is usually created under the skin in the lower part of the arm. An access needs time to heal before it can be used.",
"     </p>",
"     <p>",
"      There are 3 different types of access:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        AV fistula &mdash; Most people get this type of access (",
"        <a class=\"graphic graphic_figure graphicRef71644 \" href=\"UTD.htm?6/38/6753\">",
"         figure 2",
"        </a>",
"        ). To make this access, a doctor does surgery to connect an artery directly to a vein. An AV fistula needs to heal for 2 to 4 months before it can be used for dialysis.",
"       </li>",
"       <li>",
"        AV graft &mdash; To make this access, a doctor uses a rubber tube to connect an artery to a vein (",
"        <a class=\"graphic graphic_figure graphicRef59794 \" href=\"UTD.htm?23/45/24273\">",
"         figure 3",
"        </a>",
"        ). An AV graft needs to heal for 2 weeks before it can be used for dialysis.",
"       </li>",
"       <li>",
"        Central venous catheter &mdash; To make this access, a doctor puts a tube in a large vein (usually in the neck) (",
"        <a class=\"graphic graphic_figure graphicRef69685 \" href=\"UTD.htm?37/5/37969\">",
"         figure 4",
"        </a>",
"        ). This access is usually used only short-term or if people don&rsquo;t have any other access. It doesn&rsquo;t work as well as an AV fistula or AV graft.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24824195\">",
"      <span class=\"h1\">",
"       How do I take care of my access?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To take care of your access, you should wash it with soap and warm water every day and before each dialysis treatment.",
"     </p>",
"     <p>",
"      You should NOT:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Scratch or pick at it",
"       </li>",
"       <li>",
"        Wear tight clothes or jewelry on that arm",
"       </li>",
"       <li>",
"        Sleep on that arm",
"       </li>",
"       <li>",
"        Let anyone take blood from or measure blood pressure in that arm",
"       </li>",
"       <li>",
"        Hurt that arm",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It&rsquo;s also very important that you check your access every day to make sure that it&rsquo;s working normally and blood is flowing through it. When your access is working normally, you should be able to feel a vibration (called a &ldquo;thrill&rdquo;) over the area.",
"     </p>",
"     <p>",
"      Problems can sometimes happen with an access. Call your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You don&rsquo;t feel a vibration &mdash; This could mean that your access has stopped working or closed up.",
"       </li>",
"       <li>",
"        Your access is red or warm &mdash; This could mean that your access is infected.",
"       </li>",
"       <li>",
"        Your access bleeds a lot after hemodialysis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24824202\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=see_link\">",
"       Patient information: Hemodialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"       Patient information: Chronic kidney disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=see_link\">",
"       Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=see_link\">",
"       Patient information: Dialysis and diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/19/41266?source=see_link\">",
"       Patient information: Low-sodium diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=see_link\">",
"       Patient information: Peritoneal dialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=see_link\">",
"       Patient information: Kidney transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=see_link\">",
"       Patient information: Planning for a kidney transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/33/8722?source=see_link\">",
"       Patient information: Low-potassium diet (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       Patient information: Hemodialysis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"       Patient information: Low sodium diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42640?source=see_link\">",
"       Patient information: Low potassium diet (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/22/11619?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16270 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11619=[""].join("\n");
var outline_f11_22_11619=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24824174\">",
"      What is hemodialysis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24824181\">",
"      When do I prepare for hemodialysis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24824188\">",
"      How do I prepare for hemodialysis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24824195\">",
"      How do I take care of my access?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24824202\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16270\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/5/93\">",
"      Hemodialysis",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/38/6753\">",
"       Diagram showing AV fistula for hemodialysis",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/45/24273\">",
"        Diagram showing AV graft for hemodialysis",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/5/37969\">",
"         Diagram showing central venous catheter for hemodialysis",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/42/19107?source=related_link\">",
"      Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=related_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=related_link\">",
"      Patient information: Dialysis and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=related_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=related_link\">",
"      Patient information: Kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42640?source=related_link\">",
"      Patient information: Low potassium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/33/8722?source=related_link\">",
"      Patient information: Low-potassium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/19/41266?source=related_link\">",
"      Patient information: Low-sodium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=related_link\">",
"      Patient information: Peritoneal dialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=related_link\">",
"      Patient information: Planning for a kidney transplant (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_22_11620="Magnesium L-lactate: Drug information";
var content_f11_22_11620=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium L-lactate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44595?source=see_link\">",
"    see \"Magnesium L-lactate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3022928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mag-Tab&reg; SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3022932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Electrolyte Supplement;",
"     </li>",
"     <li>",
"      Magnesium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3022964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dietary supplement: Oral:1-2 caplets every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      RDA (elemental magnesium):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     19-30 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 310 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 350 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     &ge;31 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 320 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 420 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3022963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      RDA (elemental magnesium):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 80 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 130 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 240 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 410 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3022965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3022966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use with caution; monitor for hypermagnesemia",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3022970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, sustained release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mag-Tab&reg; SR: Elemental magnesium 84 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3022930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3022968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Should be administered with food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3022935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3022945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined: Gastrointestinal: Diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3022940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3022941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Constipation (self-medication, OTC use): Appropriate use: For occasional use only; serious side effects may occur with prolonged use. For use only under the supervision of a healthcare provider in patients with kidney dysfunction, or with a sudden change in bowel habits which persist for &gt;2 weeks. Do not use if abdominal pain, nausea, or vomiting are present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3022950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3022936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama, 1998; Osada, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3022939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions. Magnesium requirements are the same in lactating and nonlactating females (IOM, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3022967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Should be taken with food. Whole grains, legumes, and dark-green leafy vegetables are dietary sources of magnesium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6073943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Mag-Tab SR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     84 MG (7MEQ) (100): $24.93",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3022955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Serum magnesium: 1.5-2.5 mg/dL; slightly different ranges are reported by different laboratories",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3022953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium is important as a cofactor in many enzymatic reactions in the body involving protein synthesis and carbohydrate metabolism (at least 300 enzymatic reactions require magnesium). Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol and on sodium/potassium ATPase in promoting polarization (eg, neuromuscular functioning).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3022956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Inversely proportional to amount ingested; 40% to 60% under controlled dietary conditions; 15% to 36% at higher doses; majority occurs in jejunum and ileum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Bone (50% to 60%); extracellular fluid (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 30%, to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 41%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as magnesium)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bashuk RG and Krendel DA, &ldquo;Myasthenia Gravis Presenting as Weakness After Magnesium Administration,&rdquo;",
"      <i>",
"       Muscle Nerve",
"      </i>",
"      , 1990, 13(8):708-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/22/11620/abstract-text/2385256/pubmed\" id=\"2385256\" target=\"_blank\">",
"        2385256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gams JG, &ldquo;Clinical Significance of Magnesium: A Review,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(3):240-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/22/11620/abstract-text/3552543/pubmed\" id=\"3552543\" target=\"_blank\">",
"        3552543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Idama TO and Lindow SW, \"Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,\"",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1998, 105(3):260-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/22/11620/abstract-text/9532984/pubmed\" id=\"9532984\" target=\"_blank\">",
"        9532984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute of Medicine (IOM),",
"      <i>",
"       Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride",
"      </i>",
"      , National Academy of Sciences, Washington, DC, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osada H, Watanabe Y, Nishimura Y, et al, \"Profile of Trace Element Concentrations in the Feto-placental Unit in Relation to Fetal Growth,\"",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 2002, 81(10):931-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/22/11620/abstract-text/12366483/pubmed\" id=\"12366483\" target=\"_blank\">",
"        12366483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10125 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11620=[""].join("\n");
var outline_f11_22_11620=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022928\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022932\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022964\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022963\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022965\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022966\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022970\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022930\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022968\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022935\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022945\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022940\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022941\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299637\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022950\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022936\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022939\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022967\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6073943\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022955\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022953\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3022956\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10125\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10125|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44595?source=related_link\">",
"      Magnesium L-lactate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_22_11621="Ashman phenomenon in AF";
var content_f11_22_11621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1130px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Functional right bundle branch block (RBBB) in atrial fibrillation occurring in the short cycle following a preceding long cycle that lengthened the refractory period in the right bundle branch (the ashman phenomenon)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 80px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11621=[""].join("\n");
var outline_f11_22_11621=null;
var title_f11_22_11622="Technique for Z-track injection";
var content_f11_22_11622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F69880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F69880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Technique for Z-track injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 420px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Step 1: By blocking the needle pathway after an injection, the Z-track technique allows I.M. injection while minimizing the risk of subcutaneous irritation. The illustrations here show how to perform a Z-track injection. Before the procedure begins, the skin, subcutaneous fat, and muscle lie in their normal positions.",
"    <br>",
"     (B) Step 2: To begin, place your finger on the skin surface, and pull the skin and subcutaneous layers out of alignment with the underlying muscle. You should move the skin about 1 cm.",
"     <br>",
"      (C) Step 3: Insert the needle at a 90-degree angle approximately 1.5 inches at the site where you initially placed your finger. Inject the drug and withdraw the needle.",
"      <br>",
"       (D) Step 4: Finally, remove your finger from the skin surface, allowing the layers to return to their normal positions. The needle track (shown by the dotted line) is now broken at the junction of each tissue layer, trapping the drug in the muscle.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Nursing Procedures, 4th Edition. Ambler: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11622=[""].join("\n");
var outline_f11_22_11622=null;
var title_f11_22_11623="Musculoskeletal manifestations of amyloidosis";
var content_f11_22_11623=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Musculoskeletal manifestations of amyloidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/22/11623/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/22/11623/contributors\">",
"     Peter D Gorevic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/22/11623/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/22/11623/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/22/11623/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/22/11623/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/22/11623/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis refers to the extracellular tissue deposition of fibrils that are composed of low molecular weight subunits (5 to 25 kD) of a variety of serum proteins. These fibrils adopt a beta-pleated sheet configuration that is reflected in characteristic histologic changes. Amyloid deposits can occur in a variety of organs, with involvement of the heart, kidney, gastrointestinal tract, and nervous system often responsible for morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link\">",
"     \"An overview of amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The identity of the fibril subunit protein varies with the type of amyloidosis. It is a monoclonal immunoglobulin light chain or light chain fragment in AL (primary) amyloidosis (which is a plasma cell dyscrasia), a fragment of serum amyloid A protein in AA (secondary) amyloidosis, which is associated with chronic inflammatory disorders, and beta 2 microglobulin in dialysis-related amyloidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=see_link\">",
"     \"Pathogenesis of secondary (AA) amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Musculoskeletal manifestations due to amyloid deposition may be subtle, subclinical, and only apparent when a tissue biopsy is carried out [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/1\">",
"     1",
"    </a>",
"    ]. Rarely, patients present with a clinical picture that simulates a known rheumatic disease.",
"   </p>",
"   <p>",
"    In addition, musculoskeletal disorders may be the cause rather than the result of AA amyloidosis. The rheumatic and other disorders associated with AA amyloidosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=see_link\">",
"     \"Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AL (PRIMARY) AMYLOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal manifestations of AL amyloid include muscle weakness and enlargement due to amyloid infiltration (myopathy), disorders of the joints (arthropathy), and lesions of bone (osteopathy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Muscle involvement in AL amyloid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid infiltration of muscles may cause visible enlargement (ie, pseudohypertrophy) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A large tongue (ie, macroglossia) or lateral scalloping of the tongue from impingement on the teeth is characteristic of AL amyloid [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/4\">",
"     4",
"    </a>",
"    ]. Muscle infiltration is generally associated with widespread or systemic involvement. In a retrospective study conducted at a single tertiary center, 12 patients with biopsy-proven amyloid myopathy were identified over a 35-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/5\">",
"     5",
"    </a>",
"    ]. Muscular pseudohypertrophy was present in one-quarter of these patients. Muscle involvement accompanied widespread organ involvement in most patients and was associated with a median survival of 12 months. A significant number of these patients had electrophysiologic abnormalities, reflecting direct involvement or associated neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myopathy may occasionally be the initial presenting feature of AL amyloid; the diagnosis may be suggested by unusual MRI findings and confirmed by biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. A spectrum of light chain deposition and pathologies may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/10\">",
"     10",
"    </a>",
"    ]. Rarely, the presentation can simulate polymyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Arthropathy due to AL amyloid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid deposits in AL amyloidosis can involve the synovium, leading to rheumatic symptoms. As an example, amyloid arthropathy is a rare complication of Waldenstr&ouml;m's macroglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/12\">",
"     12",
"    </a>",
"    ], and an erosive arthritis has been described in patients with monoclonal gammopathy of uncertain significance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/13\">",
"     13",
"    </a>",
"    ]. Amyloid arthropathy may occur in 0.1 to 6 percent of patients with multiple myeloma, with an onset either coincident with or subsequent to the diagnosis of myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More typically, the arthropathy in AL amyloid is low-grade, subacute, progressive, and symmetric, with a predilection for the shoulders, knees, wrists, and metacarpophalangeal and proximal interphalangeal joints and, to a lesser degree, for the elbows and hips. The joints are mildly tender or nontender, and there is usually little morning stiffness.",
"   </p>",
"   <p>",
"    These characteristics help distinguish this disorder from rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, a potentially misleading finding is the presence of whitish subcutaneous nodules in about 60 percent of cases; these nodules are typically in and around the joint and are on the extensor surfaces of the forearms and elsewhere. A biopsy demonstrating Congo red birefringent material will clearly distinguish these lesions from rheumatoid nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic features include juxtaarticular cyst formation, widening of the joint space early in the disease, and soft tissue infiltration in a periarticular distribution that may be demonstrable by MR imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of other rheumatic manifestations may also be observed in AL amyloid:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Soft tissue swelling may be prominent in up to 75 percent of cases due to a nodular hypertrophied synovium directly infiltrated by amyloid. Swelling may be particularly prominent around the glenohumeral joint, resulting in a characteristic &ldquo;shoulder pad&rdquo; sign [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/18\">",
"       18",
"      </a>",
"      ]. Direct extraction of amyloid from tissue taken at the time of synovectomy in one case yielded three subunit proteins, all derived from the same VkI light chain as determined by their amino terminal sequence [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/19\">",
"       19",
"      </a>",
"      ]. In another study, a VkIII protein was extracted from the synovium of a patient with AL amyloid manifesting as a shoulder pad sign [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When the hand is involved, there may be nodularity and thickening of the palmar fascia, with 50 percent of patients developing flexion contractures and weakness. Erosions and joint space narrowing are prominently absent, and there may even be widening of the joint space radiographically. Aspirated joint fluid is usually noninflammatory, with predominantly mononuclear cells; the fluid may appear cloudy due to the presence of synovial fragments, which can be shown to contain amyloid by Congo red staining of the spun sediment [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/14,21\">",
"       14,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hand involvement is commonly associated with carpal tunnel syndrome, which is typically bilateral and symmetric. Nodular masses accumulate in the carpal tunnel and are often grossly apparent at the time of surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rarely, Charcot-like arthropathy may result from severe amyloid neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one series, soft tissue, bone, and joint manifestations were identified for 42.9 percent of 191 patients with AL amyloidosis and were found to be the dominant organ system involvement for 9.4 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/24\">",
"       24",
"      </a>",
"      ]. The most common findings were submandibular gland enlargement (31.9 percent), macroglossia (23 percent), carpal tunnel syndrome (CTS) (13.1 percent), amyloid arthropathy (3.7 percent), and pseudohypertrophy of skeletal muscles (1.6 percent). Soft tissue and bone involvement were more common among patients with multiple organ involvement and were 3.9- to 4.3-fold higher among patients found to have underlying multiple myeloma and twofold higher among men than among women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Osteopathy due to AL amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized solitary tumoral or multiple osteolytic lesions of bone may be filled with amyloid. These lesions may lead to pathologic fractures and bone pain, possibly suggesting an underlying malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/25-27\">",
"     25-27",
"    </a>",
"    ], and may cause significant neurologic deficits in multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     AL amyloid simulating other rheumatic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;AL amyloid should be considered in the differential diagnosis of jaw claudication along with giant cell",
"    <span class=\"nowrap\">",
"     arteritis/polymyalgia",
"    </span>",
"    rheumatica [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/29\">",
"     29",
"    </a>",
"    ]. Jaw claudication is due to predominantly vascular amyloid that compromises the lumina of the facial branches of the external carotid artery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/30\">",
"     30",
"    </a>",
"    ]. The presence of a monoclonal gammopathy and lack of response to corticosteroids suggest the diagnosis of AL amyloid [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sicca syndrome can occur due to amyloid deposits leading to enlargement and compromised function of both parotid and lacrimal glands [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This entity may be more prevalent than previously recognized, as evidenced by the high diagnostic yield of biopsy of the minor salivary lip glands in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nodular amyloid in the lung and skin can complicate Sj&ouml;gren's syndrome. In some cases, however, the amyloid deposits are due to monoclonal light chains and may be either a localized form of amyloidosis or a systemic light chain deposition due to concomitant multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cutaneous disease mimicking scleroderma may be the presenting feature of AL amyloid, usually associated with multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/40\">",
"     40",
"    </a>",
"    ] .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIALYSIS-RELATED AMYLOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal manifestations of dialysis-related amyloidosis, including carpal tunnel syndrome, periarthritis of the shoulder, effusive arthropathy, and erosive bone lesions, are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OSTEOARTICULAR AMYLOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microdeposits of amyloid have been found as incidental findings in the fibrous capsules, cartilage, and synovial membranes of hip joints sampled by closed synovial membrane biopsy or at surgery for osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/41\">",
"     41",
"    </a>",
"    ], in fragments of menisci accessed by arthroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/42\">",
"     42",
"    </a>",
"    ], and in biopsies of the supraspinatus tendons of patients undergoing rotator cuff surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/43\">",
"     43",
"    </a>",
"    ]. These deposits can also be commonly demonstrated at postmortem examination in the hip, in the fibrocartilaginous discs of sternoclavicular joints, and in the intervertebral discs, both in the annulus fibrosus between collagen bundles and in the nucleus pulposus [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. The incidence of osteoarticular amyloid varies with the age of the individual [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least some forms of osteoarticular amyloid appear to be localized at the site of origin, as suggested by the lack of proximity to blood vessels or evidence of congophilic angiopathy and by the location deep in relatively acellular matrix material. A direct relationship to aging appears to be more important than to osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/47\">",
"     47",
"    </a>",
"    ], and an association with calcium pyrophosphate dihydrate crystals has been noted by several investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Similar pathologic changes have been found in articular cartilage, joint capsules, and annulus fibrosus of the intervertebral discs of certain AKR-derived senescence-accelerated mouse",
"    <span class=\"nowrap\">",
"     (SAM/P)",
"    </span>",
"    lines that have served as models for spontaneous age-related amyloidosis; in these animals, both apoprotein AII and SAA were found in articular structures, with the latter correlating with systemic signs of inflammation at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amyloid extracted from the menisci of patients undergoing knee replacement surgery contains amino-terminal fragments of apolipoprotein AI (Apo A-I) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/50\">",
"     50",
"    </a>",
"    ]. Immunohistochemistry, immunostaining, and in situ hybridization suggested that the Apo A-I in the amyloid deposits originated from adjacent chondrocytes. A survey of osteoarthritic hips taken at the time of surgery implicated transthyretin (TTR) as the main immunoreactivity detected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FAMILIAL AMYLOIDOTIC POLYNEUROPATHY (FAP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthropathy and muscle involvement may occur in patients with familial amyloidotic polyneuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Arthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of sensation to a joint may result in a chronic, progressive, and destructive arthropathy. The prototype of this disorder was described by Charcot in relation to tabes dorsalis. Similar changes are seen with other neurologic disorders, such as syringomyelia and diabetic neuropathy. Erosive and Charcot-like arthropathy, in some instances associated with intraarticular amyloid deposition due to variant transthyretin subunit proteins, has been described in specific kindreds affected by FAP [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical and imaging features of the neuropathic arthropathy in patients with FAP are similar to those seen in diabetic polyneuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39527?source=see_link\">",
"     \"Diabetic neuropathic arthropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Muscle involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid angiopathy may contribute to muscle weakness and atrophy that may be a prominent feature in some kindreds affected by FAP [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12764777\">",
"    <span class=\"h2\">",
"     Nerve involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser microdissection and mass spectroscopic-based proteomics of nerve biopsies have been shown to be an effective way of classifying and characterizing AL and FAP-associated proteins causing polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11623/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INCLUSION BODY MYOSITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another form of amyloid myopathy may be inclusion body myositis, which is the most common cause for metabolic myopathy occurring in older individuals. The importance of amyloid in the etiopathogenesis of this disorder remains uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42121?source=see_link&amp;anchor=H18308499#H18308499\">",
"     \"Pathogenesis of inflammatory myopathies\", section on 'Beta-amyloid (A-beta) mediated myofiber injury'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1296950\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AL amyloid can cause muscle weakness and, in a minority of patients, can result in enlargement of muscles, termed pseudohypertrophy, due to amyloid infiltration. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Muscle involvement in AL amyloid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amyloid deposits in AL amyloidosis can involve the synovium, leading typically to a low-grade, subacute, progressive, and symmetric arthropathy, with a predilection for the shoulders, knees, wrists, and metacarpophalangeal and proximal interphalangeal joints. The joints are mildly tender or nontender, and there is usually little morning stiffness. Nodules containing amyloid may develop. Amyloid arthropathy is a very infrequent complication of multiple myeloma or other paraproteinemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Arthropathy due to AL amyloid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Localized solitary tumoral or multiple osteolytic lesions of bone containing amyloid may develop in patients with AL amyloidosis. These lesions may lead to pathologic fractures and bone pain. Other rheumatic manifestations of AL amyloid include jaw claudication that mimic giant cell arteritis due to vascular amyloid and sicca syndrome due to exocrine gland involvement. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Osteopathy due to AL amyloidosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'AL amyloid simulating other rheumatic diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Musculoskeletal manifestations of dialysis-related amyloidosis include carpal tunnel syndrome, periarthritis of the shoulder, effusive arthropathy, and erosive bone lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"       \"Dialysis-related amyloidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Microdeposits of amyloid have been found as incidental findings in the fibrous tissues, cartilage, menisci, and synovial membranes of various joints and in the annulus fibrosus and nucleus pulposus in the spine. The incidence of osteoarticular amyloid increases with advancing age. Some of these deposits contain apolipoprotein AI. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Osteoarticular amyloidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arthropathy and muscle involvement may occur in patients with familial amyloidotic polyneuropathy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Arthropathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Muscle involvement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/1\">",
"      Spuler S, Emslie-Smith A, Engel AG. Amyloid myopathy: an underdiagnosed entity. Ann Neurol 1998; 43:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/2\">",
"      Lawson TM, Bevan MA, Williams BD. Clinical images: Skeletal muscle pseudo-hypertrophy in myeloma-associated amyloidosis. Arthritis Rheum 2002; 46:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/3\">",
"      Windhagen A, Bufler J, Neudecker S. Gross muscle pseudohypertrophy in myeloma-associated light chain amyloidosis. Neurology 2005; 65:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/4\">",
"      Dhir V, Shukla S, Haroon N, et al. Medical image. Arthritis and macroglossia. Multiple myeloma complicated by amyloidosis causing arthropathy. N Z Med J 2007; 120:U2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/5\">",
"      Gertz MA, Kyle RA. Myopathy in primary systemic amyloidosis. J Neurol Neurosurg Psychiatry 1996; 60:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/6\">",
"      Rubin DI, Hermann RC. Electrophysiologic findings in amyloid myopathy. Muscle Nerve 1999; 22:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/7\">",
"      Karacostas D, Soumpourou M, Mavromatis I, et al. Isolated myopathy as the initial manifestation of primary systemic amyloidosis. J Neurol 2005; 252:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/8\">",
"      Hull KM, Griffith L, Kuncl RW, Wigley FM. A deceptive case of amyloid myopathy: clinical and magnetic resonance imaging features. Arthritis Rheum 2001; 44:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/9\">",
"      Kyriakides T, Marquez B, Panousopoulos A, et al. Amyloid myopathy: evidence for mechanical injury to the sarcolemma. Clin Neuropathol 2002; 21:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/10\">",
"      Ostrow LW, Corse AM, Morrison BM, et al. Expanding the spectrum of monoclonal light chain deposition disease in muscle. Muscle Nerve 2012; 45:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/11\">",
"      Mandl LA, Folkerth RD, Pick MA, et al. Amyloid myopathy masquerading as polymyositis. J Rheumatol 2000; 27:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/12\">",
"      Gisserot O, Landais C, Cremades S, et al. Amyloid arthropathy and Waldenstr&ouml;m macroglobulinemia. Joint Bone Spine 2006; 73:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/13\">",
"      Vitali C, Baglioni P, Vivaldi I, et al. Erosive arthritis in monoclonal gammopathy of uncertain significance: report of four cases. Arthritis Rheum 1991; 34:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/14\">",
"      Fautrel B, Fermand JP, Sibilia J, et al. Amyloid arthropathy in the course of multiple myeloma. J Rheumatol 2002; 29:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/15\">",
"      Katoh N, Tazawa K, Ishii W, et al. Systemic AL amyloidosis mimicking rheumatoid arthritis. Intern Med 2008; 47:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/16\">",
"      Fujishima M, Komatsuda A, Imai H, et al. Amyloid arthropathy resembling seronegative rheumatoid arthritis in a patient with IgD-kappa multiple myeloma. Intern Med 2003; 42:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/17\">",
"      Wiernik PH. Amyloid joint disease. Medicine (Baltimore) 1972; 51:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/18\">",
"      Edelson JG. Amyloid shoulder pads. Two cases of multiple myeloma. Acta Orthop Scand 1995; 66:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/19\">",
"      Pras M, Itzchaki M, Prelli F, et al. Amyloid arthropathy: characterization of the amyloid protein. Clin Exp Rheumatol 1985; 3:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/20\">",
"      Liepnieks JJ, Burt C, Benson MD. Shoulder-pad sign of amyloidosis: structure of an Ig kappa III protein. Scand J Immunol 2001; 54:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/21\">",
"      Gordon DA, Pruzanski W, Ogryzlo MA. Synovial fluid examination for the diagnosis of amyloidosis. Ann Rheum Dis 1973; 32:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/22\">",
"      Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/23\">",
"      Scott RB, Elmore SM, Brackett NC Jr, et al. Neuropathic joint disease (Charcot joints) in Waldenstr&ouml;m's macroglobulinemia with amyloidosis. Am J Med 1973; 54:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/24\">",
"      Prokaeva T, Spencer B, Kaut M, et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum 2007; 56:3858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/25\">",
"      Subbarao K, Jacobson HG. Amyloidosis and plasma cell dyscrasias of the musculoskeletal system. Semin Roentgenol 1986; 21:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/26\">",
"      Pambuccian SE, Horyd ID, Cawte T, Huvos AG. Amyloidoma of bone, a plasma cell/plasmacytoid neoplasm. Report of three cases and review of the literature. Am J Surg Pathol 1997; 21:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/27\">",
"      Kirkel DM, Paal E, Ascensao J, Schechter GP. Multiple bony amyloidomas as an initial presentation of myeloma. Clin Lymphoma Myeloma 2009; 9:E18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/28\">",
"      McKechnie S, Yang F, Harper CG, et al. Amyloidoma of a spinal root. Neurology 2003; 61:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/29\">",
"      Salvarani C, Gabriel SE, Gertz MA, et al. Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 1994; 37:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/30\">",
"      Churchill CH, Abril A, Krishna M, et al. Jaw claudication in primary amyloidosis: unusual presentation of a rare disease. J Rheumatol 2003; 30:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/31\">",
"      Estrada A, Stenzel TT, Burchette JL, Allen NB. Multiple myeloma-associated amyloidosis and giant cell arteritis. Arthritis Rheum 1998; 41:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/32\">",
"      Audemard A, Boutemy J, Galateau-Salle F, et al. AL amyloidosis with temporal artery involvement simulates giant-cell arteritis. Joint Bone Spine 2012; 79:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/33\">",
"      Schima W, Amann G, Steiner E, et al. Case report: sicca syndrome due to primary amyloidosis. Br J Radiol 1994; 67:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/34\">",
"      Jardinet D, Westhovens R, Peeters J. Sicca syndrome as an initial symptom of amyloidosis. Clin Rheumatol 1998; 17:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/35\">",
"      Hachulla E, Janin A, Flipo RM, et al. Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients. Arthritis Rheum 1993; 36:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/36\">",
"      Foli A, Palladini G, Caporali R, et al. The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid 2011; 18 Suppl 1:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/37\">",
"      Inazumi T, Hakuno M, Yamada H, et al. Characterization of the amyloid fibril from primary localized cutaneous nodular amyloidosis associated with Sj&ouml;gren's syndrome. Dermatology 1994; 189:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/38\">",
"      Meijer JM, Schonland SO, Palladini G, et al. Sj&ouml;gren's syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity? Arthritis Rheum 2008; 58:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/39\">",
"      Perlat A, Decaux O, Gervais R, et al. Systemic light chain amyloidosis and Sjogren syndrome: an uncommon association. Amyloid 2009; 16:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/40\">",
"      Reyes CM, Rudinskaya A, Kloss R, et al. Scleroderma-like illness as a presenting feature of multiple myeloma and amyloidosis. J Clin Rheumatol 2008; 14:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/41\">",
"      Ladefoged C, Merrild U, J&oslash;rgensen B. Amyloid deposits in surgically removed articular and periarticular tissue. Histopathology 1989; 15:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/42\">",
"      Rumpelt HJ, Braun A, Spier R, et al. Localized amyloid in the menisci of the knee joint. Pathol Res Pract 1996; 192:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/43\">",
"      Cole AS, Cordiner-Lawrie S, Carr AJ, Athanasou NA. Localised deposition of amyloid in tears of the rotator cuff. J Bone Joint Surg Br 2001; 83:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/44\">",
"      Goffin YA, Thoua Y, Potvliege PR. Microdeposition of amyloid in the joints. Ann Rheum Dis 1981; 40:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/45\">",
"      Mohr W, Kuhn C, Linke RP, Wessinghage D. Deposition of amyloid of unknown origin in articular cartilage. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 60:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/46\">",
"      Wullbrand A, Saeger W, Missmahl HP, et al. Amyloid in intervertebral discs of surgery and autopsy material. A new class of amyloid? Virchows Arch A Pathol Anat Histopathol 1990; 416:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/47\">",
"      Goffin YA, McCrickard EL, Ameryckx JP, et al. Amyloidosis of the joints: evidence that human hip capsules have a unique predisposition for amyloid of the senile systemic type. Appl Pathol 1985; 3:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/48\">",
"      Egan MS, Goldenberg DL, Cohen AS, Segal D. The association of amyloid deposits and osteoarthritis. Arthritis Rheum 1982; 25:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/49\">",
"      Shimizu K, Higuchi K, Matsushita M, et al. Immunohistochemical studies of age-associated amyloid deposition in the joint of senescence-accelerated mouse (SAM). Z Rheumatol 1992; 51:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/50\">",
"      Solomon A, Murphy CL, Kestler D, et al. Amyloid contained in the knee joint meniscus is formed from apolipoprotein A-I. Arthritis Rheum 2006; 54:3545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/51\">",
"      Niggemeyer O, Steinhagen J, Deuretzbacher G, et al. Amyloid deposition in osteoarthritis of the hip. Arch Orthop Trauma Surg 2011; 131:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/52\">",
"      Eyanson S, Benson MD. Erosive arthritis in hereditary amyloidosis. Arthritis Rheum 1983; 26:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/53\">",
"      Shiraishi M, Ando Y, Mizuta H, et al. Charcot knee arthropathy with articular amyloid deposition in familial amyloidotic polyneuropathy. Scand J Rheumatol 1997; 26:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/54\">",
"      Yamashita T, Ando Y, Katsuragi S, et al. Muscular amyloid angiopathy with amyloidgenic transthyretin Ser50Ile and Tyr114Cys. Muscle Nerve 2005; 31:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11623/abstract/55\">",
"      Klein CJ, Vrana JA, Theis JD, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011; 68:195.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5616 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11623=[""].join("\n");
var outline_f11_22_11623=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1296950\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AL (PRIMARY) AMYLOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Muscle involvement in AL amyloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Arthropathy due to AL amyloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Osteopathy due to AL amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AL amyloid simulating other rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIALYSIS-RELATED AMYLOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OSTEOARTICULAR AMYLOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FAMILIAL AMYLOIDOTIC POLYNEUROPATHY (FAP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Arthropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Muscle involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12764777\">",
"      Nerve involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INCLUSION BODY MYOSITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1296950\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=related_link\">",
"      Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39527?source=related_link\">",
"      Diabetic neuropathic arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42121?source=related_link\">",
"      Pathogenesis of inflammatory myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_22_11624="Acinar cell carcinoma";
var content_f11_22_11624=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histologic appearance of acinar cell carcinoma, moderately differentiated",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acini are identifiable and some lumens contain eosinophilic secretion (arrow). The tumor has more fibrous stroma than normal acinar tissue. Hematoxylin and Eosin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel S Longnecker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11624=[""].join("\n");
var outline_f11_22_11624=null;
var title_f11_22_11625="Mahaim tachy and AVNRT";
var content_f11_22_11625=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    AVNRT and Mahaim fiber tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram from a patient with both atrioventricular nodal reentrant tachycardia (AVNRT) and Mahaim fiber tachycardia. The initial portion of the ECG shows a narrow QRS complex AVNRT at a rate of 180 beats/min. A brief burst of ventricular pacing terminates the AVNRT but initiates a Mahaim fiber tachycardia at a rate of 150 beats/min. The QRS is wide and there is a left bundle branch block morphology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11625=[""].join("\n");
var outline_f11_22_11625=null;
var title_f11_22_11626="Initial treatment of dermatomyositis and polymyositis in adults";
var content_f11_22_11626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of dermatomyositis and polymyositis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/22/11626/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/22/11626/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/22/11626/contributors\">",
"     Stacy A Rudnicki, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/22/11626/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/22/11626/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/22/11626/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/22/11626/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/22/11626/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/22/11626/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatomyositis (DM) and polymyositis (PM) are classified as idiopathic inflammatory myopathies. Defining the optimal treatment regimens for these disorders has been difficult because of the rarity of these disorders, their highly complex clinical phenotypes, and the limited number of randomized, double-blind clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, understanding of the inflammatory myopathies has evolved over the years, but disease classification schemes have not kept pace. Newer classifications, based upon histologic and serologic distinctions between the different disorders, may help define the natural history of these diseases better, may assist in the design of well-conceived randomized clinical trials, and may lead to the development of rational therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial therapy of DM and PM will be reviewed here. The treatment of recurrent or resistant disease, the clinical manifestations and approach to diagnosis of these disorders in adults, the management of cutaneous manifestations of dermatomyositis, and issues related to DM and PM in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15513?source=see_link\">",
"     \"Initial management of cutaneous dermatomyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38281?source=see_link\">",
"     \"Management of refractory cutaneous dermatomyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2138?source=see_link\">",
"     \"Treatment and prognosis of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREDICTORS OF OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of disease in DM and PM is highly variable, ranging from mild weakness that responds readily to treatment to muscle dysfunction associated with a relentless downhill course that is unresponsive to all treatment modalities. Some clinical and laboratory features are associated with a poorer prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies that have investigated prognosis in the inflammatory myopathies did not distinguish between DM and PM. Many also did not recognize inclusion body myositis, a common mimic of PM that is associated with a worse prognosis but was not defined until the 1980s. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following clinical features have been associated with a worse outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delay in the initiation of treatment for more than six months after symptom onset [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Greater weakness at presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The presence of dysphagia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Respiratory muscle weakness [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Interstitial lung disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Associated malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cardiac involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=see_link\">",
"     \"Malignancy in dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased age has been associated with worse prognosis in some studies but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. Sex, race, the presence or absence of rash, and the height of the serum creatine kinase (CK) elevation do not predict the course of disease or the response to treatment reliably [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The lack of predictive value of the CK level may reflect the sequential changes in CK that can occur during the course of the disease: maximal elevation early, with a gradual decrease thereafter due to progressive muscle damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inflammatory myopathies are associated with an increase in mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/13\">",
"     13",
"    </a>",
"    ]. The five-year survival ranged from 52 to 65 percent in studies from 1971 to 1985, improving to 75 to 95 percent in studies from 2001 to 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/13\">",
"     13",
"    </a>",
"    ]. The most common causes of death in patients with inflammatory myopathies are malignancies, infection, respiratory failure, and cardiovascular disease. Important predictors of mortality are age, cardiovascular involvement, and respiratory compromise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type of myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new approach to classification of inflammatory myopathy suggests that patients with PM have a lower likelihood of responding to glucocorticoids alone than do patients with DM or myositis associated with a connective tissue disease (so-called &ldquo;overlap&rdquo; myositis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of diagnosis in the response to steroids was evaluated in a study that classified 100 patients using extensive testing for myositis-specific autoantibodies as well as clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/4\">",
"     4",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with PM, 50 percent were refractory to glucocorticoids.",
"     </li>",
"     <li>",
"      Among patients with DM, 87 percent responded to their initial courses of glucocorticoids. However, 92 percent flared when glucocorticoid therapy was tapered.",
"     </li>",
"     <li>",
"      Among patients with overlap myositis, the response rate to glucocorticoids ranged from 89 to 100 percent; the variability was related to the specific antibodies that were present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Myositis-specific autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain myositis-specific autoantibodies may define clinically discrete subgroups that have some predictive value for the response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/4,7,14\">",
"     4,7,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common myositis-specific autoantibody in DM and PM is the anti-Jo-1 antibody, directed against histidyl-tRNA synthase. Patients with anti-Jo-1 antibodies tend to have an incomplete response to treatment and a worse long-term prognosis. The worse outcome may be related to the interstitial lung disease often seen in association with this antibody [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/7,15\">",
"       7,15",
"      </a>",
"      ]. Antibody levels and disease activity may be correlated [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/16\">",
"       16",
"      </a>",
"      ]. Further investigation is needed before any recommendation can be made regarding serial measurement of anti-Jo-1 antibody levels.",
"     </li>",
"     <li>",
"      Some patients with anti-signal recognition particle (SRP) antibodies have a more fulminant onset of proximal muscle weakness, very high serum CK levels, and muscle biopsies that show muscle fiber necrosis and regeneration but little to no inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. Early treatment with glucocorticoids is beneficial in some of these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with anti-Mi-2 antibodies, which only occur in DM, often have a fulminant onset and florid cutaneous findings. However, they also respond well to treatment and have a good long-term prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/4,7,14,19\">",
"       4,7,14,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In overlap myositis, the autoantibody profile may also predict disease course. In a review that included 67 patients with overlap myositis, anti-RNP, anti-PM-Scl, and anti-Ku antibodies (present in 16 patients) were markers for monophasic episodes of myositis in 100 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/4\">",
"       4",
"      </a>",
"      ]. In contrast, the presence of anti-synthetase, anti-SRP, or nucleoporin autoantibodies (present in 25 patients) was a marker for chronic disease in 95 percent of the evaluable patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the future, myositis-specific autoantibody testing will play an increasingly important role in the selection of treatment for DM and PM and in the assessment of prognosis. However, their full implications related to the choice of therapies are not clear, as studies to date have been based upon small numbers of patients. Confirmation in larger studies is needed before treatment regimens can be predicated upon the pattern of myositis-specific autoantibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment are to improve muscle strength and to avoid the development of extramuscular complications. In patients with DM, resolution of cutaneous disease manifestations is an additional goal.",
"   </p>",
"   <p>",
"    Despite the absence of placebo-controlled trials demonstrating their effectiveness, glucocorticoids are the cornerstone of initial therapy for DM and PM. Some clinicians also begin treatment immediately with a glucocorticoid-sparing agent, generally",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , particularly in patients who are severely ill. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Glucocorticoid-sparing agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although older studies were unable to demonstrate an improvement in survival with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/9,20\">",
"     9,20",
"    </a>",
"    ], there is a general consensus that glucocorticoid therapy improves strength and preserves muscle function [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/21\">",
"     21",
"    </a>",
"    ]. In a National Institutes of Health series, for example, 39 percent of 113 glucocorticoid-treated patients had complete normalization of serum enzymes, and 25 percent regained full muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome of patients in community hospital settings may be better than those presumably more ill patients in tertiary care settings. As an example, in a report of 27 patients, 17 (64 percent) had little or no weakness after glucocorticoid therapy, and 11 (41 percent) achieved prolonged remissions off all medications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should inform patients at the start of therapy that they will be on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in tapering doses for approximately one year, depending upon their response to therapy and achievement of disease control. Discussion of the potential side effects of glucocorticoids is essential so that patients know what to anticipate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no standard glucocorticoid regimen for treating the inflammatory myopathies, but two general principles apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiation of treatment with high doses for the first several months to establish disease control",
"     </li>",
"     <li>",
"      Slow taper to the lowest effective dose for a total duration of therapy between 9 and 12 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Initial glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy in DM or PM is typically initiated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, to a maximum daily dose of 80 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/21\">",
"     21",
"    </a>",
"    ]. Pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1000 mg per day for three days) may be used at the start of therapy for patients who are severely ill.",
"   </p>",
"   <p>",
"    For the first four to six weeks of therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is continued at 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day with ongoing assessment of the clinical response. Maintenance of the prednisone dose at 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day beyond six weeks may increase the risk of developing glucocorticoid myopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Assessing treatment response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to glucocorticoids should be assessed every few weeks after the start of therapy. Some patients begin to show improvement in muscle strength within several weeks of starting treatment. Others improve more slowly, with clear progress not evident for three months or longer. In DM, the time courses of cutaneous responses to therapy are similar: some patients respond promptly, and, in others, improvement is more delayed.",
"   </p>",
"   <p>",
"    Once treatment has begun, the clinician should select several muscle groups to test on a regular basis as the primary gauge of clinical progress. It is useful to determine which muscles are the weakest for a given patient and to test these muscles sequentially over time. Since proximal muscles are typically most involved, the following muscle groups are often tested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower extremity:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Quadriceps &mdash; asking the patient to extend the lower leg against resistance with the limb flexed at the hip and knee",
"     </li>",
"     <li>",
"      Hip flexors &mdash; asking the patient to flex the thigh against resistance with the leg flexed at the knee and hip",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proximal lower extremity strength, including the quadriceps and other muscles, may also be evaluated by asking the patient to cross his or her arms and to rise from a chair, using only the proximal leg muscles.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper extremity and neck:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Deltoids &mdash; asking the patient to bend his or her arms at the elbow and then to extend the arms against the examiner's pressure",
"     </li>",
"     <li>",
"      Neck flexors &mdash; asking the patient to push his or her head forward while the examiner applies reverse pressure against the forehead",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It may also be worthwhile to follow changes in vital capacity as the patient is being treated.",
"   </p>",
"   <p>",
"    A central tenet of assessing the treatment response is that improvements in muscle strength are a more reliable indicator of clinical progress than are serum muscle enzyme concentrations. Declines in serum enzyme levels can be expected within two weeks of the initiation of therapy, but normalization may take considerably longer. Adjusting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    doses in attempts to normalize serum muscle enzyme concentrations may lead to overtreatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Glucocorticoid tapering",
"    </span>",
"    &nbsp;&mdash;&nbsp;After four to six weeks at the initial dose,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    tapering should begin. If patients have not demonstrated signs of clinical improvement by this time, a glucocorticoid-sparing agent should be added if such treatment was not begun simultaneously with glucocorticoid therapy. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Glucocorticoid-sparing agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is no standard tapering regimen for the inflammatory myopathies, but regimens similar to the one outlined below are often used. Assuming that a patient begins",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    treatment at 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and remains on this dose for six weeks, the following taper will require a total of 26 weeks to reach a daily dose of 5 mg:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose should be tapered by 10 mg each week until a dose of 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      is reached.",
"     </li>",
"     <li>",
"      After one week on 40",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose should be tapered by 5 mg each week until the patient reaches 20",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      After one week on 20",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose should be tapered by 2.5 mg each week until the patient reaches 10",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      After one week on 10",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose should be tapered by 1 mg every two weeks until the patient reaches 5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Deviations from this regimen may be necessary if patients develop glucocorticoid myopathy or experience disease flares. Continuation of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper can be considered if the patient has achieved and maintained good disease control. Tapering off prednisone completely should not proceed faster than 1 mg decreases every two weeks.",
"   </p>",
"   <p>",
"    The patient should be monitored carefully during the tapering period and should be watched for signs of recurrent weakness, extramuscular complications of DM or PM, and signs of glucocorticoid toxicity. The recurrence of proximal muscle weakness in a patient treated for a prolonged period with glucocorticoids poses a significant clinical conundrum, as steroid myopathy also affects the proximal musculature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Alternate-day glucocorticoid tapers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some clinicians use alternate-day glucocorticoid tapers for the treatment of inflammatory myopathies, there is little indication that such regimens are associated with less toxicity compared with the conventional regimen outlined above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Glucocorticoid responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, more than 80 percent of patients with inflammatory myopathies improve with glucocorticoids alone. However, as noted above, as many as 50 percent of patients with PM do not respond to glucocorticoid therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, among patients who do respond, the majority do not return to normal muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Type of myositis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Apparent glucocorticoid failures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of apparent failure to respond to glucocorticoids, three possibilities should be reviewed before intensifying immunosuppression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alternative diagnoses such as inclusion body myositis, muscular dystrophy, or hypothyroidism should be considered. Repeat muscle biopsies may need to be performed.",
"     </li>",
"     <li>",
"      If the diagnosis of DM or PM is confirmed, glucocorticoid-induced myopathy should be considered if the patient remains weak or has developed recurrent weakness in the setting of normal muscle enzyme levels. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"       \"Glucocorticoid-induced myopathy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Continued evidence of fibrillation potentials and positive sharp waves on EMG suggests active myositis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/23\">",
"       23",
"      </a>",
"      ]. Because of the patchy nature of inflammation and the fact that inactivity may cause type 2 muscle fiber atrophy, muscle biopsy may not always help in distinguishing glucocorticoid-induced myopathy from poorly controlled myositis. The potential utility of magnetic resonance imaging to distinguish between glucocorticoid-induced myopathy and active myositis remains undefined.",
"      <br/>",
"      <br/>",
"      An empiric trial of lowering the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose and observing the muscle strength response is a practical approach to this dilemma.",
"     </li>",
"     <li>",
"      An unrecognized malignancy associated with myositis may be a cause of failed response to glucocorticoids. Most myositis-associated malignancies are diagnosed within the two-year period before and after the development of myositis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=see_link\">",
"       \"Malignancy in dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In evaluating patients with inflammatory myopathies for potential malignancy, the recommended approach is to perform a comprehensive history and physical examination, routine laboratory testing, and a chest X-ray. Age-appropriate cancer screening is justified, but &ldquo;fishing expeditions&rdquo; are discouraged. A full discussion of the approach to screening patients with DM or PM for malignancy is provided separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=see_link\">",
"       \"Malignancy in dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once alternative underlying diagnoses, glucocorticoid myopathy, and occult malignancy have been excluded satisfactorily, the next step is the addition of a glucocorticoid-sparing agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID-SPARING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians initiate a glucocorticoid-sparing agent at the same time treatment is begun. Others reserve these agents for patients who fail treatment with glucocorticoids alone. Because of the potential for these medications to reduce the cumulative dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and thereby diminish glucocorticoid-induced morbidity, we suggest starting a glucocorticoid-sparing agent at the time prednisone therapy is initiated. For patients in whom glucocorticoids are contraindicated, these steroid-sparing agents are occasionally used as a first-line drug.",
"   </p>",
"   <p>",
"    The current first-line glucocorticoid-sparing agent is usually either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . These drugs have not been compared directly in a clinical trial. Because of hepatotoxicity and pulmonary toxicity associated with methotrexate, azathioprine is preferred in patients who have interstitial lung disease associated with their myositis, have underlying liver disease, or are unwilling to abstain from alcohol.",
"   </p>",
"   <p>",
"    Starting a glucocorticoid-sparing agent simultaneously with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may prevent intermediate and long-term side effects, particularly in patients with concomitant medical problems such as diabetes. In addition, those patients with profound weakness or significant extramuscular complications warrant treatment with two drugs from the outset. As examples, patients with interstitial lung disease or severe esophageal dysfunction are candidates for a glucocorticoid-sparing agent from the start of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial of 16 patients compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    with prednisone alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/1\">",
"     1",
"    </a>",
"    ]. At three months, there was no difference between the treatment groups in muscle strength or CK levels. However, at three years, patients treated with combination therapy had better functional outcomes and required less prednisone as maintenance therapy (1.6",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    versus 8.7",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/25\">",
"     25",
"    </a>",
"    ]. The response to azathioprine may take as long as four to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Thiopurine methyltransferase testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is uncertainty regarding the benefits of routine testing for thiopurine s-methyltransferase (TPMT, MIM #187680) deficiency before beginning",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . The authors do not routinely perform such testing but initiate therapy at a low dose with close monitoring as the dose is gradually increased. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Dosing and monitoring'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    TPMT is responsible for the metabolism of thiopurines, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    . Variation in the TPMT gene can result in functional inactivation of the enzyme and a markedly increased risk of life-threatening myelosuppression. For this reason, TPMT testing is recommended by the US Food and Drug Administration prior to treatment with a thiopurine. However, TPMT genotyping has not been universally adopted, and the cost effectiveness and optimal clinical circumstances in which to perform routine testing are not well defined.",
"   </p>",
"   <p>",
"    Expert opinions differ regarding the role of TPMT genotyping prior to the administration of thiopurines for treatment of inflammatory and autoimmune disorders. Some advocate routine testing while others, citing the low frequency of homozygous variants among Caucasians and the fact that the majority of patients who develop myelosuppression while taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    do not have detectable TPMT gene mutations, disagree with this approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of pharmacogenomics\", section on 'Thiopurine methyltransferase'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H2#H2\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Pharmacology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Dosing and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use an initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    of 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and obtain a complete blood count after two weeks of therapy to assure that the counts are stable. We then increase the daily dose by 50 mg each week to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg/day.",
"    </span>",
"    In patients with an inadequate response after three months of therapy, we increase the dose as tolerated up to as high as 2.5",
"    <span class=\"nowrap\">",
"     mg/kg/day.",
"    </span>",
"    We obtain complete blood counts, a platelet count, and liver function tests monthly initially, and, once a stable dose is achieved, we perform testing every three months.",
"   </p>",
"   <p>",
"    Alternative approaches, including more gradual dose escalation and more frequent monitoring, are recommended by some experts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Dosing and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines for dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , which are based upon TPMT genotype, have been developed for use in those patients in whom TPMT testing has been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic flu-like reactions associated with fever and gastrointestinal complaints develop in up to 12 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . These reactions are independent of TPMT status and require discontinuation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/29\">",
"     29",
"    </a>",
"    ]. Other side effects include bone marrow suppression, pancreatitis, and liver toxicity. Long-term side effects may include increased risk of malignancy. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     \"Azathioprine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;No placebo controlled prospective study has been done in DM or PM using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Several retrospective series have found response rates ranging from 71 to 82 percent, even in patients who initially failed glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/7,30-32\">",
"     7,30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    has an advantage over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in convenience, requiring only once-a-week administration either orally or parenterally. The initial dose is usually 15",
"    <span class=\"nowrap\">",
"     mg/week,",
"    </span>",
"    increasing slowly by 2.5 mg increments to 25",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    if there is inadequate response to the lower dose after two to three months.",
"   </p>",
"   <p>",
"    When used in doses above 25",
"    <span class=\"nowrap\">",
"     mg/week,",
"    </span>",
"    oral administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is usually replaced by the subcutaneous, intramuscular, or intravenous route, depending upon the clinical setting.",
"   </p>",
"   <p>",
"    Doses up to 50",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/33\">",
"     33",
"    </a>",
"    ], but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue is required for doses higher than 25",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/32\">",
"     32",
"    </a>",
"    ]. For leucovorin rescue, 5 mg of folinic acid is given once weekly, 8 to 12 hours after MTX administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    toxicity, including stomatitis, gastrointestinal symptoms, and leukopenia, can be seen with low-dose therapy. This risk can be minimized by the concurrent administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or, in patients who do not respond completely to folic acid, by the use of folinic acid (5 mg per week, 8 to 12 hours after the methotrexate dose). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of potential hepatotoxicity, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    may be problematic in patients with a history of liver disease or in those who drink alcohol, even in modest quantities.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is preferred in patients with liver disease and in those unwilling to abstain from alcohol, although it also can cause abnormalities in liver function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    pulmonary toxicity is more common in patients with myositis-associated interstitial lung disease. However, the development of methotrexate pneumonitis in a myositis patient presents diagnostic difficulties. In addition, the patient's already compromised pulmonary function increases the risk for a bad outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Antimalarials",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    (200 to 400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is effective in up to 75 percent of patients in controlling skin disease but without any benefit to muscle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Refractory rash'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional glucocorticoid-sparing therapies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\", section on 'Resistant disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients wish to discontinue immunosuppressive therapy at some point if the disease is well-controlled. However, there are no studies that address the question of the optimal duration.",
"   </p>",
"   <p>",
"    We attempt to discontinue all immunosuppressive medications after the first round of therapy, with careful monitoring by the patient and clinician for early signs of relapse.",
"   </p>",
"   <p>",
"    Most patients and clinicians prefer to discontinue glucocorticoids before stopping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Attempts to taper azathioprine or methotrexate gradually are reasonable in patients who have achieved remission and have discontinued glucocorticoids.",
"   </p>",
"   <p>",
"    The glucocorticoid tapering regimen is described above. If there are no disease flares during the course of the taper, most patients discontinue glucocorticoids at 9 to 12 months. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Glucocorticoid tapering'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Tapering of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    should be conducted at monthly intervals after the patient is in clinical remission, with planned cessation of therapy over approximately six months. The patient's clinical status must be closely monitored to permit early detection of disease flares, at a severity that does not require the resumption of high-dose glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     LONG-TERM FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up data on patients with inflammatory myopathy are few. One study followed 165 patients for a median of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/34\">",
"     34",
"    </a>",
"    ]. Of the 165 patients, 157 (95 percent) were treated with glucocorticoids and 94 (57 percent) with other immunosuppressive or immunomodulating agents. Sixty percent of the patients had courses characterized as chronic, 20 percent had polycyclic disease courses, and 20 percent had monophasic courses.",
"   </p>",
"   <p>",
"    Side effects of therapy included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cushingoid appearance (71 percent)",
"     </li>",
"     <li>",
"      Psychological or psychiatric symptoms (35 percent)",
"     </li>",
"     <li>",
"      Osteoporosis (29 percent)",
"     </li>",
"     <li>",
"      Infections (29 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Malignancy developed in five patients following the diagnosis of inflammatory myopathy. Thirty-four patients died over the course of follow-up, including 18 deaths related directly to myositis, 7 to cancer, 4 to pulmonary complications, and 4 to complications of medications.",
"   </p>",
"   <p>",
"    Among the 110 patients (84 percent of the 131 survivors) re-examined after a mean of five years, 24 percent had considerable disability, 25 percent had significant muscle weakness, and 84 percent had an abnormal quality of life.",
"   </p>",
"   <p>",
"    Forty-one percent of patients were still using more than 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or an immunosuppressive agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RECURRENT AND RESISTANT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients either relapse after an initial response or fail to respond to the above regimens. The management of such patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES AND EXTRAMUSCULAR MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to drug therapy, there are a variety of other important considerations in the treatment of patients with inflammatory myopathy. These include the initiation of an exercise program under the supervision of a physical therapist, steps to prevent aspiration in patients with esophageal dysfunction, counseling about the need for patients with DM to avoid ultraviolet light, and prophylaxis against osteoporosis and opportunistic infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large studies of the role of exercise during rehabilitation for inflammatory myopathy have not been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/35\">",
"     35",
"    </a>",
"    ]. However, observational studies support the concept that physical therapy and rehabilitation should begin early in the course of treatment, with regimens tailored to the severity of weakness:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bed or chair-bound patients with severe weakness should receive passive range of motion exercises to prevent joint contractures. Careful attention to positioning reduces the risk of pressure sores.",
"     </li>",
"     <li>",
"      Isometric and resistive exercises should begin as soon as the patient has recovered enough strength to be able to participate.",
"     </li>",
"     <li>",
"      Patients with less severe weakness should be encouraged to participate in an active exercise program, progressing as tolerated from lower level isometric exercises to more vigorous isotonic exercises.",
"     </li>",
"     <li>",
"      Patients with mild weakness should be encouraged to continue reasonable levels of activity as tolerated [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/36\">",
"       36",
"      </a>",
"      ]. Appropriate exercise programs do not cause increased serum CK levels or delay recovery of muscle strength, even during periods of active disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Aspiration risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with dysphagia due to cricopharyngeal muscle dysfunction are at risk for aspiration. Several interventions can reduce this risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Speech therapy consultation for advice about aspiration risk and precautions.",
"     </li>",
"     <li>",
"      Elevation of the head of the bed.",
"     </li>",
"     <li>",
"      Semi-thick diets.",
"     </li>",
"     <li>",
"      A nasopharyngeal or gastric feeding tube may be necessary to provide adequate nutrition and to help protect the airway in patients with severe dysphagia.",
"     </li>",
"     <li>",
"      Patients with myositis and overlap with scleroderma may develop reflux esophagitis due to incompetence of the lower esophageal sphincter. Treatment with proton pump inhibitors decreases both the risk of stricture formation and reflux symptoms, but some patients have persistent symptoms. The treatment of refractory gastroesophageal reflux is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=see_link\">",
"       \"Approach to refractory gastroesophageal reflux disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H402183\">",
"    <span class=\"h2\">",
"     Skin disease and avoidance of sunlight",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous manifestations of dermatomyositis frequently respond to the agents used to treat the associated myositis, including glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . However, skin manifestations can persist despite effective treatment of myositis. Therapy for cutaneous disease is usually indicated due to the presence of severe pruritus and patient distress over the appearance of skin lesions. The treatment of the cutaneous manifestations of dermatomyositis is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15513?source=see_link\">",
"     \"Initial management of cutaneous dermatomyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38281?source=see_link\">",
"     \"Management of refractory cutaneous dermatomyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Scrupulous protection from the sun, including liberal use of sunscreens and sun-protective clothing, is important because the rashes are often related to photosensitivity. Patients can also benefit from use of topical corticosteroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15513?source=see_link&amp;anchor=H13069036#H13069036\">",
"     \"Initial management of cutaneous dermatomyositis\", section on 'Photoprotection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15513?source=see_link&amp;anchor=H13069050#H13069050\">",
"     \"Initial management of cutaneous dermatomyositis\", section on 'Topical corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antimalarial drugs can be used to treat the skin disease in patients with prominent rash or dermatomyositis sine myositis (amyopathic dermatomyositis). In such patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ) used in combination with quinacrine may be effective if HCQ alone is inadequate. In addition, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    can be effective for skin lesions refractory to other therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15513?source=see_link&amp;anchor=H11395989#H11395989\">",
"     \"Initial management of cutaneous dermatomyositis\", section on 'Systemic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15513?source=see_link&amp;anchor=H377187#H377187\">",
"     \"Initial management of cutaneous dermatomyositis\", section on 'Management of pruritus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus is often a significant complaint. Various topical remedies used include menthol, camphor, antihistamines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/5/17491?source=see_link\">",
"     pramoxine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . Systemic agents used include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15513?source=see_link&amp;anchor=H377187#H377187\">",
"     \"Initial management of cutaneous dermatomyositis\", section on 'Management of pruritus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Osteoporosis prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients treated with high-dose glucocorticoids are at risk for glucocorticoid-induced osteoporosis. Thus, all patients embarking upon treatment courses for inflammatory myopathy are potential candidates for antiresorptive therapy designed to prevent bone loss.",
"   </p>",
"   <p>",
"    The prevention and treatment of glucocorticoid-induced osteoporosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Opportunistic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high-dose glucocorticoid therapy and other immunosuppressive medications used to treat inflammatory myopathy, patients with DM and PM are at an increased risk for opportunistic infection. Pneumocystis jirovecii, a common pathogen in immunosuppressed hosts, may cause lethal infections, particularly in patients with interstitial lung disease. Fungal and mycobacterial infections of the lung and gastrointestinal tract and herpesvirus infections may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link&amp;anchor=H12#H12\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylaxis against pneumocystic jirovecii is, thus, often indicated for patients treated with high-dose glucocorticoids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other immunosuppressive agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link&amp;anchor=H12#H12\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A common prophylactic strategy for Pneumocystis involves the use of one double-strength tablet daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    <span class=\"nowrap\">",
"     (TMP/SMZ),",
"    </span>",
"    which contains 160 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    and 800 mg of sulfamethoxazole. Because both trimethoprim and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    are folate antagonists, some have raised concerns that the use of double-strength",
"    <span class=\"nowrap\">",
"     TMP/SMZ",
"    </span>",
"    tablets on a daily basis combined with weekly methotrexate may lead to bone marrow suppression. For myositis patients treated with methotrexate, daily single-strength",
"    <span class=\"nowrap\">",
"     TMP/SMZ",
"    </span>",
"    (80 mg of trimethoprim and 400 mg of sulfamethoxazole) is likely to be safe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcomes of pregnancy in patients with DM and PM and the influence of pregnancy on the activity of inflammatory muscle disease are both issues for which there are few data. One summary of these issues included four cases and a review of 39 other pregnancies in a total of 33 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/40\">",
"     40",
"    </a>",
"    ]. In this study, there was no consistent effect of pregnancy on the mothers' disease activity. The outcomes of the pregnancies were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 29 pregnancies in 20 women with DM (including one twin pregnancy), the outcomes were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      15 healthy full-term births",
"     </li>",
"     <li>",
"      7 miscarriages, stillbirths, or abortions",
"     </li>",
"     <li>",
"      3 premature births",
"     </li>",
"     <li>",
"      3 pregnancies with intrauterine growth retardation (IUGR)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 13 women with PM, the outcomes were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      8 healthy infants",
"     </li>",
"     <li>",
"      2 pregnancies complicated by IUGR",
"     </li>",
"     <li>",
"      4 stillbirths or abortions (one therapeutic)",
"     </li>",
"     <li>",
"      2 premature births (one followed by neonatal death).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Healthy births appeared to be more likely when myositis is inactive than when active disease is present during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/22/11626/abstract/40\">",
"     40",
"    </a>",
"    ]. Among the 22 women with inactive disease during pregnancy, 16 (73 percent) gave births to healthy babies. In contrast, only 7 of the 27 women (26 percent) who had active disease during pregnancy delivered healthy infants.",
"   </p>",
"   <p>",
"    Thus, if pregnancy is desired, disease manifestations should be controlled as well as possible before the patient attempts to conceive. Additional considerations in the treatment of pregnant women with inflammatory myopathy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of glucocorticoids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      appears to be relatively safe during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If teratogenic agents are necessary to control severe disease, therapeutic termination of the pregnancy should be considered, and appropriate counseling should be provided.",
"     </li>",
"     <li>",
"      Chronic use of glucocorticoids may result in suppression of the hypothalamic-pituitary-adrenal axis. Stress-dose glucocorticoids may be needed during childbirth. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/63/5106?source=see_link\">",
"       \"Patient information: Dermatomyositis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/47/30450?source=see_link\">",
"       \"Patient information: Polymyositis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=see_link\">",
"       \"Patient information: Myositis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data upon which to base treatment recommendations for adult dermatomyositis (DM) and polymyositis (PM).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Predictors of outcome",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determinants of prognosis in DM and PM include the specific type of myositis, disease severity, delay in diagnosis, the presence of selected extramuscular disease features, and autoantibody profile. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with PM are the least likely to respond to glucocorticoids alone. Those with overlap myositis are most likely. Patients with DM are likely to respond to glucocorticoids, but the majority has disease that requires ongoing therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Type of myositis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antisynthetase antibodies are often associated with interstitial lung disease, other extramuscular manifestations, and a worse long-term prognosis due to the related lung disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Myositis-specific autoantibodies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend glucocorticoids for inflammatory myopathy associated with significant muscle weakness (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We typically begin",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day and generally do not exceed 80 mg daily.",
"     </li>",
"     <li>",
"      For patients who are severely ill, we suggest initiating glucocorticoid therapy with an intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      pulse: 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three days (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest tapering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      to the lowest effective dose over a total of 9 to 12 months (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Glucocorticoid tapering'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Glucocorticoid-sparing agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest initiating a glucocorticoid-sparing agent at the same time glucocorticoids are begun (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The first-line glucocorticoid-sparing agents are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Selection between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      is guided by a variety of factors including patient preference, underlying liver or lung disease, willingness to limit alcohol intake, and deficiencies in thiopurine methyltransferase (TPMT) alleles. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Glucocorticoid-sparing agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      in patients who have interstitial lung disease associated with their myositis, have underlying liver disease, or are unwilling to abstain from alcohol (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The usual starting dose for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      is 50",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      This can be increased gradually to up to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg/day.",
"      </span>",
"      A CBC should be monitored within two weeks of starting azathioprine.",
"     </li>",
"     <li>",
"      The usual starting dose for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      is 15",
"      <span class=\"nowrap\">",
"       mg/week.",
"      </span>",
"      If there is an inadequate response after two to three months, this can be increased to 25",
"      <span class=\"nowrap\">",
"       mg/week.",
"      </span>",
"     </li>",
"     <li>",
"      Once treatment has begun, following muscle strength on serial physical examinations is a more important gauge of treatment response than are the serum concentrations of muscle enzymes.",
"     </li>",
"     <li>",
"      We suggest attempting to discontinue immunosuppressive therapy after the first round of treatment, with careful follow-up for the possibility of disease recurrence (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest tapering glucocorticoids off before beginning to taper the glucocorticoid-sparing agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the setting of apparently resistant disease, several potential scenarios should be considered:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The original diagnosis of DM or PM was incorrect.",
"     </li>",
"     <li>",
"      The patient may have developed a glucocorticoid-induced myopathy.",
"     </li>",
"     <li>",
"      An unrecognized malignancy associated with myositis may be the cause of the failure to respond to therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=see_link\">",
"     \"Malignancy in dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These issues are discussed in further detail above. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Apparent glucocorticoid failures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     General treatment measures",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical therapy and rehabilitation should begin early in the course of treatment, with regimens tailored to the severity of weakness.",
"     </li>",
"     <li>",
"      Aspiration precautions are advisable for patients with esophageal dysfunction. Speech therapy evaluations may be helpful for patients with esophageal disease.",
"     </li>",
"     <li>",
"      Patients with DM may be photosensitive and should, therefore, take measures to avoid ultraviolet light.",
"     </li>",
"     <li>",
"      Glucocorticoid-induced osteoporosis can be an important cause of long-term treatment-related morbidity. We recommend that measures should be taken for the prevention of glucocorticoid-induced osteoporosis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ), which can be an important cause of long-term treatment-related morbidity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients treated with the combination of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and any other immunosuppressive agent, we suggest prophylaxis against Pneumocystis jirovecii infections (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For Pneumocystis prophylaxis, one appropriate regimen is a single-strength tablet of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (80",
"      <span class=\"nowrap\">",
"       mg/400",
"      </span>",
"      mg) each day. Daily double-strength",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      -sulfamethoxazole tablets should not be used in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      If female patients desire to become pregnant, disease manifestations should be as well-controlled as possible before the patient attempts to conceive.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/1\">",
"      Bunch TW, Worthington JW, Combs JJ, et al. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980; 92:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/2\">",
"      Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/3\">",
"      Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992; 326:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/4\">",
"      Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005; 84:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/5\">",
"      Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/6\">",
"      Isenberg DA, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/7\">",
"      Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993; 94:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/8\">",
"      Fafalak RG, Peterson MG, Kagen LJ. Strength in polymyositis and dermatomyositis: best outcome in patients treated early. J Rheumatol 1994; 21:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/9\">",
"      Carpenter JR, Bunch TW, Engel AG, O'Brien PC. Survival in polymyositis: corticosteroids and risk factors. J Rheumatol 1977; 4:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/10\">",
"      Dank&oacute; K, Ponyi A, Constantin T, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004; 83:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/11\">",
"      Maugars YM, Berthelot JM, Abbas AA, et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996; 14:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/12\">",
"      Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999; 78:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/13\">",
"      Lundberg IE, Forbess CJ. Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol 2008; 26:S109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/14\">",
"      Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/15\">",
"      Plotz PH, Rider LG, Targoff IN, et al. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995; 122:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/16\">",
"      Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007; 56:3125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/17\">",
"      Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/18\">",
"      Kao AH, Lacomis D, Lucas M, et al. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/19\">",
"      Targoff IN. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am 1994; 20:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/20\">",
"      Winkelmann RK, Mulder DW, Lambert EH, et al. Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients. Mayo Clin Proc 1968; 43:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/21\">",
"      Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol 1996; 34:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/22\">",
"      Hoffman GS, Franck WA, Raddatz DA, Stallones L. Presentation, treatment, and prognosis of idiopathic inflammatory muscle disease in a rural hospital. Am J Med 1983; 75:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/23\">",
"      Robinson LR. AAEM case report #22: polymyositis. Muscle Nerve 1991; 14:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/24\">",
"      Sigurgeirsson B, Lindel&ouml;f B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/25\">",
"      Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 1981; 24:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/26\">",
"      Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/27\">",
"      Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol 2003; 16:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/28\">",
"      Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/29\">",
"      Kissel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. Neurology 1986; 36:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/30\">",
"      Giannini M, Callen JP. Treatment of dermatomyositis with methotrexate and prednisone. Arch Dermatol 1979; 115:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/31\">",
"      Newman ED, Scott DW. The Use of Low-dose Oral Methotrexate in the Treatment of Polymyositis and Dermatomyositis. J Clin Rheumatol 1995; 1:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/32\">",
"      Metzger AL, Bohan A, Goldberg LS, et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/33\">",
"      Vleugels RA, Callen JP. Dermatomyositis: current and future therapies. Expert Rev Dermatol 2009; 4:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/34\">",
"      Bronner IM, van der Meulen MF, de Visser M, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006; 65:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/35\">",
"      Alexanderson H, Lundberg IE. The role of exercise in the rehabilitation of idiopathic inflammatory myopathies. Curr Opin Rheumatol 2005; 17:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/36\">",
"      Dastmalchi M, Alexanderson H, Loell I, et al. Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum 2007; 57:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/37\">",
"      Hicks JE, Miller F, Plotz P, et al. Isometric exercise increases strength and does not produce sustained creatinine phosphokinase increases in a patient with polymyositis. J Rheumatol 1993; 20:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/38\">",
"      Marie I, Hachulla E, Ch&eacute;rin P, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005; 53:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/39\">",
"      Fardet L, Rybojad M, Gain M, et al. Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm. Arch Dermatol 2009; 145:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/22/11626/abstract/40\">",
"      Silva CA, Sultan SM, Isenberg DA. Pregnancy outcome in adult-onset idiopathic inflammatory myopathy. Rheumatology (Oxford) 2003; 42:1168.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5160 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-2F8DE301F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11626=[""].join("\n");
var outline_f11_22_11626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREDICTORS OF OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical predictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type of myositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Myositis-specific autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - General approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Initial glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Assessing treatment response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Glucocorticoid tapering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Alternate-day glucocorticoid tapers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Glucocorticoid responses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Apparent glucocorticoid failures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      GLUCOCORTICOID-SPARING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Thiopurine methyltransferase testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Dosing and monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Antimalarials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      LONG-TERM FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RECURRENT AND RESISTANT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      GENERAL MEASURES AND EXTRAMUSCULAR MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Aspiration risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H402183\">",
"      Skin disease and avoidance of sunlight",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Osteoporosis prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Opportunistic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Predictors of outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Glucocorticoid-sparing agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      General treatment measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=related_link\">",
"      Approach to refractory gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=related_link\">",
"      Azathioprine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15513?source=related_link\">",
"      Initial management of cutaneous dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=related_link\">",
"      Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=related_link\">",
"      Malignancy in dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38281?source=related_link\">",
"      Management of refractory cutaneous dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/63/5106?source=related_link\">",
"      Patient information: Dermatomyositis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=related_link\">",
"      Patient information: Myositis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/47/30450?source=related_link\">",
"      Patient information: Polymyositis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2138?source=related_link\">",
"      Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=related_link\">",
"      Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_22_11627="Appropriate prescribing in the elderly";
var content_f11_22_11627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Appropriate prescribing in the elderly",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Is there an indication for the drug?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Is the medication effective for the condition?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Is the dosage correct?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Are the directions correct?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Are the directions practical?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Are there clinically significant drug-drug interactions?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Are there clinically significant drug-disease/condition interactions?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Is there unnecessary duplication with other drugs?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Is the duration of therapy acceptable?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Is this drug the least expensive alternative compared with others of equal usefulness?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol 1992; 45:1045. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11627=[""].join("\n");
var outline_f11_22_11627=null;
var title_f11_22_11628="Diff naive and memory T cells";
var content_f11_22_11628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differences between na&iuml;ve and memory T cells",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Na&iuml;ve",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effector",
"       </td>",
"       <td class=\"subtitle1\">",
"        Memory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"5\">",
"        Surface phenotype&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        CD45RA",
"       </td>",
"       <td>",
"        CD45RA/RO",
"       </td>",
"       <td>",
"        CD45RO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD44 lo",
"       </td>",
"       <td>",
"        CD44 hi",
"       </td>",
"       <td>",
"        CD44 hi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Integrins lo",
"       </td>",
"       <td>",
"        Integrins hi",
"       </td>",
"       <td>",
"        Integrins hi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD29 lo",
"       </td>",
"       <td>",
"        CD29 hi",
"       </td>",
"       <td>",
"        CD29 hi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD25 lo",
"       </td>",
"       <td>",
"        CD25 hi",
"       </td>",
"       <td>",
"        CD25 lo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Response to stimulation&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antigen/APC",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytokine production",
"       </td>",
"       <td>",
"        Mainly IL-2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Th1/Th2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low conc. Anti-CD3 Ab",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-CD2 Ab",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Need for co-stimulation",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Ab: antibody; APC: antigen presenting cell.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11628=[""].join("\n");
var outline_f11_22_11628=null;
var title_f11_22_11629="Anticoagulant coagulant herbs";
var content_f11_22_11629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anticoagulant and coagulant herbal ingredients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Anticoagulants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alfalfa",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angelica",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aniseed",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arnica",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asafoetida",
"       </td>",
"       <td>",
"        Coumarin constituents, anticoagulant in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Celery",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chamomile, German",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chamomile, Roman",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clove",
"       </td>",
"       <td>",
"        Eugenol powerful inhibitor of platelet activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fenugreek",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Feverfew",
"       </td>",
"       <td>",
"        Inhibits platelet aggregation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fucus",
"       </td>",
"       <td>",
"        Anticoagulant action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Garlic",
"       </td>",
"       <td>",
"        Interaction with warfarin reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ginger",
"       </td>",
"       <td>",
"        Inhibition of platelet activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ginseng, Panax",
"       </td>",
"       <td>",
"        Reduction of blood coagulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Horse-chestnut",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Horseradish",
"       </td>",
"       <td>",
"        Peroxidase stimulates synthesis of arachidonic acid metabolites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liquorice",
"       </td>",
"       <td>",
"        Inhibition of platelet activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meadowsweet",
"       </td>",
"       <td>",
"        Salicylate constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Poplar",
"       </td>",
"       <td>",
"        Salicylate constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prickly ash, northern",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prickly ash, southern",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quassia",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Red clover",
"       </td>",
"       <td>",
"        Coumarin constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Willow",
"       </td>",
"       <td>",
"        Salicylate constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Coagulants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Agrimony",
"       </td>",
"       <td>",
"        Coagulant, human",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Goldenseal",
"       </td>",
"       <td>",
"        Heparin antagonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mistletoe",
"       </td>",
"       <td>",
"        Lectins, agglutinating activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yarrow",
"       </td>",
"       <td>",
"        Coagulant, in vivo",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.282.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11629=[""].join("\n");
var outline_f11_22_11629=null;
var title_f11_22_11630="Dating violence in the US";
var content_f11_22_11630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percentage of high school students who experienced physical aggression by a romantic partner* and who were ever physically forced to have sexual intercourse,",
"    <sup>",
"     &bull;",
"    </sup>",
"    by sex, race/ethnicity, and grade - United States, Youth Risk Behavior Survey,",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"6\">",
"        Physical aggression by a romantic partner",
"       </td>",
"       <td class=\"small\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"6\">",
"        Forced to have sexual intercourse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Female",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Male",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Total",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Female",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Male",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Total",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        CI",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        CI",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        CI",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        CI",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        CI",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        CI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"14\">",
"        Race/ethnicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        6.3-9.4",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        6.4-8.7",
"       </td>",
"       <td>",
"        <strong>",
"         7.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         6.6-8.6",
"        </strong>",
"       </td>",
"       <td class=\"small\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        12.0",
"       </td>",
"       <td>",
"        10.3-13.8",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"       <td>",
"        2.6-3.9",
"       </td>",
"       <td>",
"        <strong>",
"         7.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         6.5-8.4",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Black",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        11.8",
"       </td>",
"       <td>",
"        9.9-14.1",
"       </td>",
"       <td>",
"        12.4",
"       </td>",
"       <td>",
"        10.6-14.4",
"       </td>",
"       <td>",
"        <strong>",
"         12.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         10.8-13.7",
"        </strong>",
"       </td>",
"       <td>",
"        11.0",
"       </td>",
"       <td>",
"        8.4-14.4",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        4.7-8.0",
"       </td>",
"       <td>",
"        <strong>",
"         8.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         7.0-10.6",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hispanic",
"       </td>",
"       <td>",
"        10.6",
"       </td>",
"       <td>",
"        9.0-12.4",
"       </td>",
"       <td>",
"        12.1",
"       </td>",
"       <td>",
"        9.7-14.9",
"       </td>",
"       <td>",
"        <strong>",
"         11.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         9.9-13.0",
"        </strong>",
"       </td>",
"       <td>",
"        11.2",
"       </td>",
"       <td>",
"        9.6-13.1",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        4.1-7.0",
"       </td>",
"       <td>",
"        <strong>",
"         8.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         7.2-9.4",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"14\">",
"        Grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        6.3-9.2",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        5.8-9.2",
"       </td>",
"       <td>",
"        <strong>",
"         7.5",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         6.4-8.8",
"        </strong>",
"       </td>",
"       <td class=\"small\" rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        8.2",
"       </td>",
"       <td>",
"        6.7-9.9",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        2.5-4.9",
"       </td>",
"       <td>",
"        <strong>",
"         5.8",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         4.9-6.9",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10",
"       </td>",
"       <td>",
"        9.8",
"       </td>",
"       <td>",
"        8.0-12.0",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        8.0-11.1",
"       </td>",
"       <td>",
"        <strong>",
"         9.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         8.4-11.0",
"        </strong>",
"       </td>",
"       <td>",
"        12.2",
"       </td>",
"       <td>",
"        10.1-14.5",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        3.2-5.6",
"       </td>",
"       <td>",
"        <strong>",
"         8.0",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         6.7-9.5",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"       <td>",
"        7.7-11.1",
"       </td>",
"       <td>",
"        11.2",
"       </td>",
"       <td>",
"        9.2-13.7",
"       </td>",
"       <td>",
"        <strong>",
"         10.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         8.7-12.1",
"        </strong>",
"       </td>",
"       <td>",
"        12.7",
"       </td>",
"       <td>",
"        10.8-14.7",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"       <td>",
"        3.9-6.9",
"       </td>",
"       <td>",
"        <strong>",
"         8.8",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         7.6-10.2",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12",
"       </td>",
"       <td>",
"        10.7",
"       </td>",
"       <td>",
"        8.7-13.0",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        8.2-12.0",
"       </td>",
"       <td>",
"        <strong>",
"         10.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         8.9-11.9",
"        </strong>",
"       </td>",
"       <td>",
"        14.5",
"       </td>",
"       <td>",
"        12.5-16.8",
"       </td>",
"       <td>",
"        4.7",
"       </td>",
"       <td>",
"        3.6-6.1",
"       </td>",
"       <td>",
"        <strong>",
"         9.5",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         8.4-10.8",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         9.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         8.2-10.5",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         9.5",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         8.5-10.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         9.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         8.6-10.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         11.8",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         10.6-13.0",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         4.5",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         3.8-5.3",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         8.0",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         7.3-8.8",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Hit, slapped, or physically hurt on purpose by their boyfriend or girlfriend during the 12 months before the survey.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     When they did not want to.",
"     <br/>",
"     &Delta; 95 percent confidence interval.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Non-Hispanic.",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012; 61:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11630=[""].join("\n");
var outline_f11_22_11630=null;
var title_f11_22_11631="Hashimotos goiter Echo";
var content_f11_22_11631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Focal lesion in Hashimoto's goiter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 214px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sonogram of the right thyroid lobe in the longitudinal plane of a large multinodular goiter due to Hashimoto's disease. The lobe had a firm prominence at its lower pole on physical examination. This photograph demonstrates an electronic assembly of two adjacent images; the seam is in the projection of the arrow. There is a complex hypoechogenic nodule (N) that expands the lower end of a 33 mm wide and 88 mm long lobe (+ + and x x). The nodule was suspicious of cancer on biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manfred Blum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_22_11631=[""].join("\n");
var outline_f11_22_11631=null;
